Inhibition of the PI3K/Akt signaling pathway reverses sorafenib-derived chemo-resistance in hepatocellular carcinoma.

about

Inhibition of the PI3K/Akt signaling pathway reverses sorafenib-derived chemo-resistance in hepatocellular carcinoma.

Item

http://www.wikidata.org/entity/Q55269976

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Inhibition of the PI3K/Akt sig ...... e in hepatocellular carcinoma.

@en

Inhibition of the PI3K/Akt sig ...... e in hepatocellular carcinoma.

@nl

type

Item

label

Inhibition of the PI3K/Akt sig ...... e in hepatocellular carcinoma.

@en

Inhibition of the PI3K/Akt sig ...... e in hepatocellular carcinoma.

@nl

prefLabel

Inhibition of the PI3K/Akt sig ...... e in hepatocellular carcinoma.

@en

Inhibition of the PI3K/Akt sig ...... e in hepatocellular carcinoma.

@nl

P1476

Inhibition of the PI3K/Akt sig ...... e in hepatocellular carcinoma.

@en

P2093

Hao Zhang

http://www.w3.org/2001/XMLSchema#string

Haoqiang Cao

http://www.w3.org/2001/XMLSchema#string

Jun Liu

http://www.w3.org/2001/XMLSchema#string

Qingqing Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition

Global cancer statistics, 2012

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Hepatocellular carcinoma

Activation of PI3K/AKT and MAPK pathway through a PDGFRβ-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma.

The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance

Sinulariolide Suppresses Human Hepatocellular Carcinoma Cell Migration and Invasion by Inhibiting Matrix Metalloproteinase-2/-9 through MAPKs and PI3K/Akt Signaling Pathways.

Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling.

Active form of AKT controls cell proliferation and response to apoptosis in hepatocellular carcinoma.

P304

9377-9384

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/OL.2018.8536

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-04-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29928334

http://www.w3.org/2001/XMLSchema#string

P932

6004698

http://www.w3.org/2001/XMLSchema#string